{"id":7176,"date":"2025-04-26T17:03:26","date_gmt":"2025-04-26T22:03:26","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=6023"},"modified":"2025-07-13T15:09:30","modified_gmt":"2025-07-13T20:09:30","slug":"nanoscope-participation-at-eyecelerator-and-arvo-2025","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","title":{"rendered":"Nanoscope Therapeutics anuncia su participaci\u00f3n en las reuniones anuales de Eyecelerator\u00ae y ARVO 2025."},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h3 class=\"prntac\" style=\"text-align: center;\"><em>Presentaciones para destacar la eficacia, durabilidad y seguridad de las plataformas de terapia optogen\u00e9tica de Nanoscope.<\/em><\/h3>\n<\/div>\n<div class=\"col-sm-4 col-xs-12 col-vcenter\">\n<div class=\"image logo logo-wrapper\" data-src=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-asset-type=\"photo\" data-asset-label=\"Logo\" data-download-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg\" data-tweet-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-pinterest-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-linkedin-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-facebook-share-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-twitter-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=twitter\" data-facebook-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=facebook\" data-pinterest-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-linkedin-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=linkedin\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">25 de abril de 2025<\/span><\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con restaurar la visi\u00f3n en pacientes ciegos en entornos del mundo real mediante el desarrollo y la comercializaci\u00f3n de nuevas terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy su participaci\u00f3n en ambos eventos.\u00a0<a href=\"https:\/\/www.eyecelerator.com\/\" target=\"_blank\" rel=\"nofollow noopener\">acelerador ocular<\/a>\u00a0y\u00a0<a href=\"https:\/\/www.arvo.org\/annual-meeting\/\" target=\"_blank\" rel=\"nofollow noopener\">La Asociaci\u00f3n para la Investigaci\u00f3n y la Visi\u00f3n en Oftalmolog\u00eda (ARVO) 2025<\/a>\u00a0reuniones anuales. Las presentaciones de Nanoscope se centrar\u00e1n en los resultados de 126 semanas despu\u00e9s del tratamiento con su\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/technology-2\/\" target=\"_blank\" rel=\"nofollow noopener\">Terapia optogen\u00e9tica MCO-010<\/a>\u00a0para la retinosis pigmentaria (RP), la primera y \u00fanica terapia\u00a0<a href=\"https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/fulltext\/S1525-0016(25)00205-9\" target=\"_blank\" rel=\"nofollow noopener\">Se ha demostrado que restaura la visi\u00f3n en pacientes con retinosis pigmentaria avanzada.<\/a>\u00a0mediante una inyecci\u00f3n intrav\u00edtrea est\u00e1ndar de una sola vez.<\/p>\n<p>\u201cEstamos encantados de tener una presencia tan importante en las reuniones anuales de Eyecelerator y ARVO, y esperamos compartir m\u00e1s informaci\u00f3n sobre los beneficios terap\u00e9uticos positivos observados en pacientes con RP tratados con nuestra terapia de opsina multicaracter\u00edstica, o MCO\u201d, dijo el Dr.\u00a0<span class=\"xn-person\">Samarendra Mohanty<\/span>, cofundador y presidente de Nanoscope. \u201cEl beneficio a largo plazo es significativo para los pacientes que buscan una opci\u00f3n de tratamiento duradera y de una sola vez para su p\u00e9rdida de visi\u00f3n progresiva e irreversible debido a la retinosis pigmentaria, y subraya el potencial de MCO-010 para redefinir el est\u00e1ndar de atenci\u00f3n. Es un momento emocionante en Nanoscope mientras preparamos MCO-010 para su comercializaci\u00f3n, incluyendo la presentaci\u00f3n de la solicitud de licencia biol\u00f3gica (BLA)\u201d.\u201d<\/p>\n<p>Los detalles de las presentaciones son los siguientes:<\/p>\n<p><b><a href=\"https:\/\/www.eyecelerator.com\/\" target=\"_blank\" rel=\"nofollow noopener\">acelerador ocular\u00a0<\/a><\/b><br class=\"dnr\" \/><span class=\"xn-chron\">Viernes, 2 de mayo<\/span><sup>Dakota del Norte<\/sup>, 2025<br class=\"dnr\" \/>Magn\u00edfico\u00a0<span class=\"xn-person\">Hyatt Deer Valley<\/span>,\u00a0<span class=\"xn-location\">Park City, Utah, EE.UU.<\/span><\/p>\n<p>Participaci\u00f3n en Nanoscope:<\/p>\n<ul type=\"disc\">\n<li><b>12:30 \u2013 13:30 MDT\u00a0<\/b>\u2013 Panel \u2013 Ser\u00e9 liberado: Nuevos enfoques de administraci\u00f3n de f\u00e1rmacos para el glaucoma y la retina \u2013 Dr.\u00a0<span class=\"xn-person\">Sam Barone<\/span>, Director M\u00e9dico<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b>13:59 \u2013 14:04 (hora de la monta\u00f1a); Sal\u00f3n Strawberry\u00a0<\/b>\u2013 Presentaci\u00f3n de la empresa: Retina: terapia g\u00e9nica y nuevos mecanismos de acci\u00f3n \u2013 Dr.\u00a0<span class=\"xn-person\">Jared Esteban<\/span>, Vicepresidente de Estrategia y Desarrollo de Negocios<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b>3:30 \u2013\u00a0<span class=\"xn-chron\">16:15<\/span><\/b>\u00a0<b>Equipo multidisciplinario<\/b>\u00a0\u2013 Panel \u2013 Sin rumbo fijo: Gu\u00eda para navegar por v\u00edas regulatorias cada vez m\u00e1s complejas \u2013 Dr.\u00a0<span class=\"xn-person\">Sam Barone<\/span><\/li>\n<\/ul>\n<p><b><a href=\"https:\/\/www.arvo.org\/annual-meeting\/\" target=\"_blank\" rel=\"nofollow noopener\">ARVO, la Asociaci\u00f3n para la Investigaci\u00f3n en Visi\u00f3n y Oftalmolog\u00eda.<\/a><br class=\"dnr\" \/><\/b><span class=\"xn-chron\">Domingo, 4 de mayo<\/span><sup>th<\/sup>\u00a0a\u00a0<span class=\"xn-chron\">Jueves, 8 de mayo<\/span><sup>th<\/sup>, 2025<br class=\"dnr\" \/>Centro de convenciones Salt Palace,\u00a0<span class=\"xn-location\">Salt Lake City, Utah<\/span><\/p>\n<p>Presentaciones de nanoscopios:<\/p>\n<ul type=\"disc\">\n<li><b><span class=\"xn-chron\">Domingo, 4 de mayo<\/span><sup>th<\/sup>, 1:30 \u2013\u00a0<span class=\"xn-chron\">13:45 MDT<\/span>; Sal\u00f3n de baile G\u00a0<\/b>- EM.\u00a0<span class=\"xn-person\">Lucero Garc\u00eda<\/span>\u00a0Presentaci\u00f3n: \u201cLa terapia g\u00e9nica con opsinas multicaracter\u00edsticas aten\u00faa la degeneraci\u00f3n retiniana y restaura la visi\u00f3n en un modelo de atrofia geogr\u00e1fica en primates no humanos\u201d.\u201d<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b><span class=\"xn-chron\">Martes, 6 de mayo<\/span><sup>th<\/sup>, 9:15 \u2013\u00a0<span class=\"xn-chron\">9:30 a. m. MDT<\/span>; Sal\u00f3n de baile B\u00a0<\/b>\u2013 Presentaci\u00f3n del Dr. SriniVas Sadda: \u201cResultados de la agudeza visual a las 126 semanas tras la terapia optogen\u00e9tica MCO-010, independiente de la mutaci\u00f3n, para la retinosis pigmentaria (RP)\u201d<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b><span class=\"xn-chron\">Jueves, 8 de mayo<\/span><sup>th<\/sup>, 2:45 \u2013\u00a0<span class=\"xn-chron\">15:00 MDT<\/span>; Sal\u00f3n de baile F\u00a0<\/b>- Dr.\u00a0<span class=\"xn-person\">Naj Sharif<\/span>\u00a0Presentaci\u00f3n: \u201cSeguridad y eficacia de la administraci\u00f3n dirigida no viral mediante l\u00e1ser guiada por im\u00e1genes de pl\u00e1smidos de opsina con m\u00faltiples caracter\u00edsticas en retinas de monos verdes africanos\u201d.\u201d<\/li>\n<\/ul>\n<p>Los miembros del equipo de Nanoscope estar\u00e1n disponibles en el stand 1337 durante toda la duraci\u00f3n de la conferencia ARVO.<\/p>\n<p><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas, independientes de las mutaciones y que restauran la visi\u00f3n, para los millones de pacientes con ceguera causada por enfermedades degenerativas de la retina para las que actualmente no existe tratamiento. Tras los resultados positivos al final del estudio RESTORE, ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo de fase 2b para la RP (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), la compa\u00f1\u00eda anunci\u00f3 su plan de iniciar un\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>\u00a0en el primer semestre de 2025. La empresa ha completado el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar una\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>, Tambi\u00e9n en 2025. MCO-010 ha recibido las designaciones de v\u00eda r\u00e1pida de la FDA y la designaci\u00f3n de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los programas precl\u00ednicos incluyen un f\u00e1rmaco MCO-020 no viral administrado por l\u00e1ser, listo para la solicitud de nuevo f\u00e1rmaco en investigaci\u00f3n (IND), para la atrofia geogr\u00e1fica (GA), as\u00ed como un f\u00e1rmaco AAV para la amaurosis cong\u00e9nita de Leber, en estudios precl\u00ednicos.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Presentations to highlight efficacy, durability, and safety of\u00a0Nanoscope\u2019s optogenetic therapy platforms DALLAS,\u00a0April 25, 2025\u00a0 \u2014 Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced participation at both the\u00a0Eyecelerator\u00a0and\u00a0The Association for Research and Vision in Ophthalmology [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":7179,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-7176","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-26T22:03:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:09:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings\",\"datePublished\":\"2025-04-26T22:03:26+00:00\",\"dateModified\":\"2025-07-13T20:09:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\"},\"wordCount\":555,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\",\"name\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"datePublished\":\"2025-04-26T22:03:26+00:00\",\"dateModified\":\"2025-07-13T20:09:30+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"width\":1000,\"height\":1000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia su participaci\u00f3n en las reuniones anuales de Eyecelerator\u00ae y ARVO 2025 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-04-26T22:03:26+00:00","article_modified_time":"2025-07-13T20:09:30+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings","datePublished":"2025-04-26T22:03:26+00:00","dateModified":"2025-07-13T20:09:30+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/"},"wordCount":555,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","url":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","name":"Nanoscope Therapeutics anuncia su participaci\u00f3n en las reuniones anuales de Eyecelerator\u00ae y ARVO 2025 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","datePublished":"2025-04-26T22:03:26+00:00","dateModified":"2025-07-13T20:09:30+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","width":1000,"height":1000},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/7176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=7176"}],"version-history":[{"count":3,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/7176\/revisions"}],"predecessor-version":[{"id":7213,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/7176\/revisions\/7213"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/7179"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=7176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=7176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=7176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}